On August 9th, Gelunhui announced that Guangdong Zhongsheng Pharmaceutical (002317.SZ), and its controlling subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as "Zhongsheng Ruichuang"), obtained a registration certificate for a type one innovative drug, Lariivir, from the Macau Special Administrative Region Government's drug supervision and management bureau.
Lariivir (brand name: Leruilin) is the world's first peptidomimetic 3CL monoantibody drug to treat COVID-19 with global independent intellectual property rights, independently developed by the company. It was conditionally approved for listing by the National Medical Products Administration in March 2023, and is used to treat adult patients with mild to moderate COVID-19. It was successfully included in the Category B of the National Medical Insurance Catalog in the same year after negotiations. Lariivir is an important antiviral product of the company. Its approval for sale in Macau is expected to benefit more COVID-19 patients, and provide a safe and effective treatment option for doctors and patients.
Lariivir does not require a CYP enzyme inhibitor, ritonavir, for combination therapy. It can significantly shorten the clinical recovery time of COVID-19 patients and significantly reduce the viral load, avoiding the clinical limitations and safety risks that may arise from the use of ritonavir in combination therapy. It provides a treatment option for COVID-19 patients who cannot or are restricted in using ritonavir due to age or underlying diseases.
